CAMP4 Therapeutics

AvenCell Therapeutics Inc is a developer of cell technology therapy that focuses on building chimeric antigen receptor T cells, thereby helping patients in cancer treatment

Stelis Biopharma (formerly Agila Specialties), a subsidiary of Strides Arcolab Ltd, is a full services player with a well diversified portfolio of products across categories that include high potency drugs like oncology, Penems, Penicillins, Cephalosporins, Ophthalmics, Peptides, Controlled Substances. In December 2013, Mylan acquired the injectable business of the company from Strides Arcolab.In September 2012, the company received approval for its 'Polish Sterile facility' in the injectables unit of Strides Acrolab Limited from the US FDA. By that time, totally eight injectable had been approved by the US FDA and European authorities cGMP manufacturing facility.In June 2011, Agila Specialties signed an agreement to establish a manufacturing plant with Bio-XCell, Malaysia. In July 2014, parent company Strides Acrolab disclosed that further delays were expected in the manufacturing facility setup in Malaysia. In December 2014, the company began construction of multi

CAMP4 Therapeutics Corp is a biotechnology company that develops a gene circuity platform intended to identify de-risked druggable targets and improve therapeutic predictability. The company leverages machine learning algorithms to code the discrete set of combinatorial rules used by any human cell type central to disease pathology and solve for druggable targets, enabling the medical community to control the output of any disease gene of interest.In June 2021, CAMP4 Therapeutics Corp had raised $45 million to drive the next phase of its scientific approach to expand its platform and advance multiple preclinical RNA therapies into human testing